Dr. Roderick Wong M.D. serves as Chairman of the Board of the Company. Dr. Wong served as the Chairperson of the Board for Private Rocket from July 2015 until January 2018. Dr. Wong has over 15 years of healthcare investment experience. Since 2010, he has served as Managing Partner and Chief Investment Officer of RTW, a healthcare-centered investment firm. Prior to RTW, Dr. Wong was a Managing Director and the Portfolio Manager for the Davidson Kempner Healthcare Funds. Prior to joining Davidson Kempner, Dr. Wong held various healthcare investment and healthcare research roles at SAC Capital Company and Cowen & Company. Dr. Wong served on the board of directors of Penwest Pharmaceuticals in 2010 and has previously served on the board of directors of Health Sciences Acquisitions Corporation. He received an M.D. from the University of Pennsylvania Medical School, received an M.B.A. from Harvard Business School, and graduated with a B.S. in Economics from Duke University.
As the Chairman of the Board of Rocket Pharmaceuticals Inc, the total compensation of Roderick Wong at Rocket Pharmaceuticals Inc is $380,761. There are 8 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.
Roderick Wong is 43, he's been the Chairman of the Board of Rocket Pharmaceuticals Inc since 2018. There are 13 older and 3 younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.
Roderick's mailing address filed with the SEC is C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY, NJ, 08512.
Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten a Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.
rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.
Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include: